C
Charles A. Dinarello
Researcher at University of Colorado Denver
Publications - 1073
Citations - 152254
Charles A. Dinarello is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Interleukin & Cytokine. The author has an hindex of 190, co-authored 1058 publications receiving 139668 citations. Previous affiliations of Charles A. Dinarello include University of Guadalajara & Pennsylvania State University.
Papers
More filters
Journal ArticleDOI
Modulatory in vitro effects of interleukin-1 receptor antagonist (IL-1Ra) or antisense oligonucleotide to interleukin-1 beta converting enzyme (ICE) on acute myeloid leukaemia (AML) cell growth.
TL;DR: Investigation of the effects of interleukin-1 receptor antagonist on the spontaneous proliferation and AML colony forming unit (CFU-AML) formation of bone marrow and peripheral blood cells in 50 acute myeloid leukaemia patients suggests that AML is a heterogenous disorder regarding IL-1 beta regulation.
Journal ArticleDOI
The effect of fish oil supplementation on plasma α-tocopherol, retionol, lipid and lipoprotein levels in normolipidemic subjects
Alice C. Shapiro,Simin Nikbin Meydani,Mohsen Meydani,Frank D. Morrow,Judith R. McNamara,Ernst J. Schaefer,Stefan Endres,Charles A. Dinarello +7 more
TL;DR: The effects of supplementing with MaxEPA fish oil (FO) on the plasma concentrations of α-tocopherol, retinol, lipids and lipoproteins in young male subjects were studied as discussed by the authors.
Journal ArticleDOI
Suppression of IL-2-induced SAA gene expression in mice by the administration of an IL-1 receptor antagonist
TL;DR: It is suggested that the production of IL-1 is an important factor in the induction of SAA mRNA in mice undergoing immunotherapy with IL-2, and the administration of theIL-1RA had no effect on circulating IL-6 levels in IL- 2-treated mice.
Journal ArticleDOI
The lysine deacetylase inhibitor Givinostat inhibits β-cell IL-1β induced IL-1β transcription and processing.
Mattias S. Dahllöf,Dan Ploug Christensen,Morten Lundh,Charles A. Dinarello,Paolo Mascagni,Lars Groth Grunnet,Thomas Mandrup-Poulsen +6 more
TL;DR: Inhibition of lysine deacetylases (KDACi) counteracts β-cell toxicity induced by the combination of IL-1 and IFNγ and reduces diabetes incidence in non-obese diabetic (NOD) mice and may be attractive novel drug targets in DM.